Patent ID: 6680326
Filing Date: 2004-01-20
Classification: A61P,C07D

Abstract:
A polycyclic compound of formula [I], wherein;ring A is a pyridine, pyrazine, pyridazine or pyrimidine ring which may be substituted by R1 and R2; R1 and R2 are independently hydrogen, halogen, (C1-C5) alkyl, hydroxy, mercapto, (C1-C5) alkoxy, (C4-C7) cycloalkyloxy, (C3-C7)cycloalkyl(C1-C5)alkyloxy, (C1-C5) alkylthio, (C1-C5) alkylsulfinyl, (C1-C5) alkylsulfonyl, amino, mono-(C1-C5)-alkylamino, di-(C1-C5)-alkylamino or â€”Yâ€²â€”Zâ€²â€”N(R6â€²)(R7â€²); wherein Yâ€² is O, S or N(R9â€²), wherein R9â€² is hydrogen or (C1-C5) alkyl; or when Yâ€² is N(R9â€²), N(R9â€²) forms an aliphatic ring together with N(R6â€²) and Zâ€²; Zâ€² is (C2-C5) alkylene; or Zâ€² forms an aliphatic ring together with N(R6â€²) and (NR9â€²); or Zâ€² forms an aliphatic ring together with N(R6â€²); R6â€² and R7â€² are independently hydrogen, (C1-C5) alkyl, (C3-C5) alkenyl, (C3-C7) cycloalkyl, (C4-C7) cycloalkyl, (C3-C7)cycloalkyl(C1-C5)alkyloxy or aryl(C1-C5)alkyl optionally substituted with one to three substituents selected form the group consisting of hydroxy, (C1-C5) alkoxy, amino, mono-(C1-C5)-alkylamino and di-(C1-C5)-alkylamino; or R6â€² and R7â€² form an aliphatic ring optionally containing one to three heteroatom(s) selected from the group consisting of oxygen, nitrogen and sulfur together with the adjacent nitrogen; or R6â€² forms an aliphatic ring together with the adjacent nitrogen and Zâ€²; or R6â€² forms an aliphatic ring together with the adjacent nitrogen, N(R9â€²) and Zâ€²; ring B is a benzene ring, naphthalene ring or benzene ring substituted with (C1-C5) alkylenedioxy group which is optionally substituted by R3, R4 and R5; R3, R4 and R5 are independently hydrogen, halogen, hydroxy, mercapto, (C1-C5) alkyl, (C1-C5) halogeno-alkyl, (C1-C5) alkoxy, (C1-C5) halogeno-alkoxy, (C3-C5) alkenyloxy, (C4-C7) cycloalkyloxy, (C3-C7)cycloalkyl(C1-C5) alkyloxy, aryl(C1-C5)alkyloxy, (C1-C5) alkylthio, (C1-C5) alkylsulfinyl, (C1-C5) alkylsulfonyl, amino, mono-(C1-C5)-alkylamino or di-(C1-C5)-alkylamino; X is O or Nâ€”Oâ€”R8 wherein R8 is a hydrogen, (C1-C5) alkyl, (C3-C5) alkenyl, (C4-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C5)alkyl, aryl, or aryl(C1-C5)alkyl; Y is O, S or N(R9) wherein R9 is hydrogen or (C1-C5) alkyl; or when Y is N(R9), N(R9) forms an aliphatic ring together with N(R6) and Z; Z is (C2-C5) alkylene optionally substituted with (C1-C5) alkyl radical(s); or Z forms an aliphatic ring together with N(R6) and N(R9); or Z forms an aliphatic ring together with N(R6); and R6 and R7 are independently hydrogen, (C1-C5) alkyl, (C3-C5) alkenyl, (C4-C7) cycloalkyl, (C3-C7)cycloalkyl(C1-C5)alkyl or aryl(C1-C5)alkyl optionally substituted with hydroxy, alkoxy, amino, mono-(C1-C5)-alkylamino and di-(C1-C5)-alkylamino; or R6 and R7 form an aliphatic ring optionally containing one to three heteroatom(s) selected from the group consisting of oxygen, nitrogen and sulfur together with the adjacent nitrogen; or R6 forms an aliphatic ring together with the adjacent nitrogen and Z; or R6 forms an aliphatic ring together with the adjacent nitrogen, N(R9) and Z, or a pharmaceutically acceptable salt thereof.